PHAXIAM Therapeutics S.A.(PHXM) - 2023 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 ________________________ PHAXIAM Therapeutics S.A. (Translation of registrant's name into English) ________________________ 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) ________________________ Indicat ...